New treatment approach for kidney cancer using a dual inhibitor
Official title: Development of a novel dual HIF-α inhibitor and inducer of ferroptosis for kidney cancer
Funded at Kuda Therapeutics, INC. · NIH-10708992 · Data updated 2026-11-12
This study is testing a new treatment for clear cell kidney cancer that aims to stop the cancer from growing by using a special drug that targets certain proteins, and it's designed for patients who haven't had success with standard therapies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kuda Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Salt Lake City, UNITED STATES) |
| Project start | June 1, 2018 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $625,000 |
| NIH project number | 5R44CA217385-04 |
| Project ID | NIH-10708992 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who have not responded to conventional treatments.
✕Less likely to help
Patients with other types of kidney cancer or those who are not eligible for experimental therapies may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for clear cell renal cell carcinoma (ccRCC), a type of kidney cancer that is resistant to standard therapies. The approach involves using a dual inhibitor that targets specific proteins involved in cancer progression and induces a form of cell death known as ferroptosis. By inhibiting these proteins, the treatment aims to reduce tumor growth and improve patient outcomes. The research includes both laboratory and animal studies to evaluate the effectiveness and safety of the new compounds.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with advanced kidney cancer.
How similar studies have gone: Previous research has shown promise in targeting HIF proteins in kidney cancer, indicating that this approach could be a significant advancement in treatment.
Where this research is happening
-
Kuda Therapeutics, INC.
Salt Lake City, United States Active
Researchers
- Principal investigator: Lippert, Robert — Kuda Therapeutics, INC.
- Study coordinator: Lippert, Robert
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
-
Kidney Cancer Development Program at DF/HCC
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.